

2 **Gastroprotective activity of methanol leaves**
3 **extract of *Barleria prionitis* Linn. on ethanol and**
4 **indomethacin induced ulcer in rats**

5 Manjusha¹, Vipin Kumar*¹, Surender Singh²

6 ¹*Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra-136119, India*

7 ²*All India Institute of Medical Sciences, New Delhi-110029, India*

8
9
10
11 **ABSTRACT**

Aims: *Barleria prionitis* L. (Family Acanthaceae) is a medicinal plant found road side in India and whole plant or its various parts like leaves, root, bark, stem and flowers are used traditionally for various treatments like toothache, inflammation, boils, glandular swellings and ulcer. Leaf juice is useful in gastric ulcer. Here, we attempt to prove the use of this plant as gastroprotective agent.

Study Design: This study was conducted to evaluate the antiulcer activity of methanol extract obtained from the leaves of *Barleria prionitis* Linn.

Place and Duration of Study: The experiments were conducted at Pharmacology lab of Institute of Pharmaceutical Sciences, Kurukshetra University during the period of July 2012 to December 2012.

Material and methods: Antiulcer activity was performed using the protocols of ulcer induced by ethanol and indomethacin at two different doses (250 and 500mg/kg). Parameters like volume of gastric juice, pH, free acidity, total acidity, aspartate amino transferase (AST) and alanine amino transferase (ALT) were also determined in ethanol induced ulcer model.

Results: The reduction in ulcer index in *Barleria prionitis* treated animals was found to be statistically significant (P=.05), when compared with control groups in both the models. Significant changes were observed in total acidity at dose 500mg/kg only and changes were significant in AST, ALT levels at both the doses. Other parameters showed non-significant results.

Conclusion: The results of the present study show that the **methanolic** extract of *Barleria prionitis* L. possess antiulcer activity. This work supports the traditional use of this plant in treating gastric ulcer.

12
13 **Keywords:** *Barleria prionitis*, Gastroprotective activity, Ulcer index, Methanol extract, Ethanol


15 1. INTRODUCTION

16
17 Gastric hyperacidity is a very common global problem that affects millions of people
18 worldwide [1,2]. In hyperacidity stomach acid levels are high in the g.i.t, on some occasions
19 this excess acid secretion can lead to inflammation, irritation or erosion of stomach mucosa
20 which is known as gastritis that can be acute (brief and sudden) and chronic (longer lasting).
21 It may provoke peptic ulcer if untreated [3,4]. An ulcer is the disruption in the skin or mucus
22 membrane lining alimentary canal. Ulceration occurs when there is imbalance between
23 aggressive (acid-pepsin secretions) and protective factors (such as mucus secretion,
24 mucosal barrier, cell regeneration, blood flow and prostaglandins) [5,6]. About 95% of ulcers
25 are duodenal, while gastric ulcers are less common. The gastric mucosa is continuously
26 exposed to various noxious agents like acid, pepsin, bile acids, bacterial products and drugs.
27 These agents have been contributed in the pathogenesis of gastric ulcers by increasing
28 gastric acid and pepsin secretion, inhibiting prostaglandin synthesis and by decreasing
29 gastric blood flow and gastric motility [7]. The current treatment of peptic ulcer is mainly done
30 with H₂ receptor antagonists, proton pump inhibitors, and antimuscarinics. But, most of these
31 treatments produce adverse reaction like, hypersensitivity, arrhythmia, impotence,
32 gynecomastia and hematopoietic disorders [8-11]. Therefore, there is requirement for new
33 and safer treatment, with fewer side effects. Plants extracts are among the suitable
34 treatments for the prevention of gastric ulcer [12].

35 *Barleria* (Acanthaceae) ia a large genus with about 230 species of herbs and shrubs
36 distributed chiefly in the tropical and subtropical parts of the world. About 30 species occur in
37 India, many of which are known for their ornamental and/or medicinal value. Some of the
38 important species of this genus are *B. prionitis*, *B. greenii*, *B. albostellata*, *B. cristata*, *B.*
39 *gibsoni*, *B. strigosa*, *B. tomentosa* etc. In some *Barleria* species biological activities such as
40 anti-inflammatory, analgesic, antileukemic and hypoglycemic have been reported [13,14].

41 *Barleria prionitis* L. common name: Vajradanti known as Sahachara in Ayurveda is a
42 medicinal plant found throughout South Africa, India, Sri-Lanka, and tropical Asia [15,16]. Its
43 leaves juice is used in stomach problems, ulcer, fever and urinary infections in indigenous
44 system of medicine of India [17]. Some Indian tribes use leaves to reduce irritation and for
45 treatment of piles [18,19]. The aerial parts are used in the fever, toothache, inflammation and
46 gastrointestinal disorder; bark in whooping cough as an expectorant. Whole plant especially
47 roots are used as tonic and diuretic [20,21]. Leaves stem and roots of plant possess anti-
48 inflammatory and antibacterial activities [22,13]. It is also used in jaundice, hepatic
49 obstruction and dropsy [23]. Iridoid rich fraction of aerial parts has been reported for
50 hepatoprotective activity [24].

51 Phytochemical studies on hydro-methanolic extract of *B. prionitis* showed the presence of
52 glycosides, steroids, tannins and flavonoids [25]. Iridoid glycosides, shanzhiside methyl
53 ester, 6-O-trans-p-coumaroyl-8-O-acetylshanzhiside methyl ester, barlerin, acetylbarlerin, 7-
54 methoxydideroside and lupuloside have been isolated from aerial parts [26]. The
55 structures of some major phytoconstituents are given in Figure 1. No study was conducted
56 scientifically to prove the gastroprotective effect of *B. prionitis* leaves. Hence the present
57 study was conducted to evaluate the antiulcer properties of methanolic extract of *B. prionitis*
58 Linn.



59 **Figure 1. Isolated phytoconstituents of *B. prionitis***

60 **2. MATERIAL AND METHODS**

61

62 **2.1 Plant material**

63 The leaves of *Barleria prionitis* were collected from Ashoka nursery Gharunda, Karnal,
64 Haryana, India in the month of March, 2011. Then, collected leaves were positively identified
65 by Dr. H.B. Singh, Head, Raw Materials Herbarium and Museum (RHMD), New Delhi. A
66 voucher specimen of the plant (Ref. No. NISCAIR/RHMD/CONSULT/-2010-11/1497/95) has
67 been preserved there for future references.

68 **2.2 Extraction**

69 The leaves were thoroughly washed under running tap water so as to remove any type of
70 contamination. Then washed leaves were air dried in shade, powdered in grinder and
71 passed through sieve of mesh size no-40. The dried powder was first defatted by petroleum
72 ether and then successive extraction was done with chloroform and methanol by hot Soxhlet
73 extraction method. The methanol extract was concentrated in a rotary evaporator under
74 reduced pressure. The dried crude extract was collected and preserved in airtight glass
75 container at 4°C - 8°C.

76 **2.3 Preliminary phytochemical studies**

77 To determine the chemical constituents, the methanol extract obtained was thus subjected to
78 phytochemical analysis [27].

79

80 **2.4 Antiulcer activity**

81 **2.4.1 Experimental animals**

82 Healthy Wistar rats of either sex were obtained from a disease free animal house of
83 Chaudhary Charan Singh, Haryana Agriculture University, Hisar, Haryana (India). The
84 animals were housed in the animal house, Institute of Pharmaceutical Sciences, Kurukshetra
85 University, Kurukshetra, Haryana (India). Rats were fed with commercially available feed
86 and were maintained under standard conditions of temperature (25°C ± 5°C), relative
87 humidity (55 ± 10%), and 12/12 h light/dark cycle. They were housed in standard
88 polycarbonate cages with wire mesh top and husk bedding.

89

90 **2.4.2 Experimental design**

91 Wistar rats weighing between 175-250 g of either sex were used for antiulcer study. All
92 animals were divided into 4 groups of 6 animals. Before the experiments, animals were
93 deprived of food but allowed free access to water.

94

95 **2.4.3 Dose and route of administration**

96 For experimentation 250mg/kg and 500mg/kg doses of *Barleria prionitis* methanolic (BPM)
97 extract were used. Fresh drug solutions were prepared in sterile distilled water at the time of
98 administration and were administered Per Oral (p.o.) so as to avoid any additional stress to
99 the animals.

100

101

102 **2.4.4 Group designing for ethanol and indomethacin induced ulcer models**
103 Group I (Control): Animals received only distilled water; Group II (BPM 250): Animals
104 received *B. prionitis* (250mg/kg, *p.o.*) 1 hr before the ulcerogenic procedure; Group III (BPM
105 500): Animals received *B. prionitis* (500mg/kg, *p.o.*) 1 hr before the ulcerogenic procedure;
106 Group IV (Standard): Animals **received** ranitidine (50mg/kg, *p.o.*) 1 hr before the ulcerogenic
107 procedure.

108 **2.4.5 Ethanol induced gastric mucosal lesions**
109 This is a widely used model that seems to cause gastric ulcer. The activity was performed
110 according to the slightly modified method of Mizui and Dotuchi [28]. Rats were fasted for 36
111 h before administration of absolute ethanol (1.0mL). The group I was given only distilled
112 water. The extract (250 mg/kg, 500mg/kg, *p.o.*) and ranitidine (50mg/kg, *p.o.*) as standard
113 drug, were given to Group II, III and IV respectively. One hour after treatment, all the rats
114 received ethanol to induce gastric ulcer. Another one hour later, animals were sacrificed by
115 cervical dislocation. The stomachs were removed, cut and opened along the greater
116 curvature, washed with normal saline to remove the gastric contents and observed for the
117 severity of the ulcers. The pH and volume of gastric juice was measured after centrifugation
118 at 2000rpm for 10 min. From the supernatant, aliquots were taken for the determination of
119 total and free acidity. The percentage protection was calculated using the following formula:-

120 $\% I = (UI \text{ of control} - UI \text{ of test}) \times 100 / UI \text{ of the control}$

121 Where I = Inhibition, UI= Ulcer index

122 **2.4.6 Ulcer indexing**
123 The mucosal layer of the stomach was observed under a magnifying lens and ulcers were
124 checked. The area (mm^2) of all lesions was measured using digital callipers' to give a gastric
125 damage score. The ulcer index was determined using the following formula [29].

126 $UI = 10/X$

127 Where X= total mucosal area/total ulcerated area

128 **2.4.7 Total acidity and free acidity determination**

129 1.00mL of centrifuged and filtered gastric juice was taken in a conical flask. Two drops of 1%
130 phenolphthalein indicator for total acidity and Topfer's reagent for free acidity was added to
131 it. It was titrated against 0.1mol/L sodium hydroxide until a permanent pink color (total
132 acidity) or canary yellow colour (free acidity) was observed. The total/free acidity is
133 expressed as meq./L by the following formula:-

134 $\text{Total/free acidity} = n \times 0.01 \times 36.45 \times 1000$

135 Where, n is the volume of NaoH consumed, 0.01 is normality of NaoH, 36.45 is molecular
136 weight of NaoH, 1000 is the factor (to be represented in litre).

137 **2.4.8 Indomethacin induced gastric ulcers**
138 In this model, the gastric lesions are induced by the inhibition of prostaglandin synthesis.
139 Activity was performed according to method of Djahanguiri [30] and 24 h fasted rats were
140 used for study. Group I animals were treated orally with distilled water. The extract (250
141 mg/kg, 500mg/kg, *p.o.*) and ranitidine (50mg/kg, *p.o.*) as standard drug, were given to Group
142 II, III and IV respectively. One hr. after the treatment, 20mg/kg of indomethacin (dissolved in
143 2% sodium bicarbonate) was administered orally. After 4 h, all animals were sacrificed by
144 cervical dislocation. The stomachs were isolated, washed with normal saline and various

145 parameters like ulcer index, free acidity and total acidity were measured as discussed above
146 [31].

147 **2.4.9 Serum biochemical parameters**

148 Blood samples were analysed for AST and ALT level estimation in ethanol induced gastric
149 lesions.

150 **2.5 Statistical analysis**

151
152 All the values were expressed as mean±standard error of mean. The statistical significance
153 of difference among groups was analysed using one-way ANOVA. A value of $P<0.05$ was
154 considered significant.

155 **3. RESULTS**

156

157 **3.1 Preliminary phytochemical screening**

158 The percentage yield of petroleum ether, chloroform and methanol leaf extracts were found
159 to be 4.9, 6.9 and 16.7% (in weight). Preliminary phytochemical screening of methanol
160 extract showed the presence of steroids, alkaloids, saponins, glycosides and flavonoids.

161 **3.2 Antiulcer activity**

162 **3.2.1. Ethanol induced gastric ulcer**

163 In this study, BPM was screened for gastroprotective activity against ethanol induced gastric
164 ulcer in rats. The absolute ethanol administration (*p.o.*) induced severe ulceration. BPM and
165 ranitidine groups showed the significant reduction in incidence and severity of ulceration.
166 BPM and ranitidine showed a significant change in ulcer index when compared with the
167 control group $P<0.01$ (Table 1). BPM and ranitidine showed slight changes in pH, volume of
168 gastric juice, free acidity and total acidity but changes were not significant when compared
169 with control group except total acidity in BPM (500mg/kg) treated group, $P<0.01$ (Table 2).

170 **Table 1. Ulcer index of ethanol and indomethacin induced gastric ulcers**

Model	Group	Dose(mg/kg body weight)	Ulcer index	% Inhibition
Ethanol	Ethanol	--	0.90±0.01	-
	BPM	250	0.43±0.02**	52.2%
	BPM	500	0.29±0.04**	67.7%
	Ranitidine	50	0.22±0.02**	75.5%
Indomethacin	Indomethacin	20	1.35±0.15	-
	BPM	250	0.51±0.03**	62.2%
	BPM	500	0.40±0.02**	70.3%
	Ranitidine	50	0.51±0.03**	62.2%

171 *Results as mean±S.E.M. for six rats. Statistical comparison was performed using ANOVA*
172 *followed by the Dunnett's test. ** $P<0.01$ when compared with control group.*

173

174

175 **Table 2. Volume of gastric juice, pH, free acidity and total acidity in ethanol induced**
176 **gastric ulcer**

Group	Dose(mg/kg)	Volume of gastric juice(ml)	pH	Free acidity(mmol/h)	Total acidity(mmol/h)
Ethanol	--	2.08±0.01	4.42±0.06	0.53±0.008	1.22±0.008
BPM	250	2.55±0.18	4.51±0.06	0.48±0.02	1.23±0.02
BPM	500	2.22±0.18	4.40±0.05	0.46±0.02	0.81±0.01**
Ranitidine	50	2.72±0.27	4.51±0.03	0.51±0.03	1.26±0.02

177 Results as mean±S.E.M. for six rats. Statistical comparison was performed using ANOVA
 178 followed by the Dunnett's test. **P<0.01 when compared with control group.

179

180

3.2.2 Biochemical parameters

181

182

183

Ethanol group induced ulcer showed a increase in liver enzymes (ALT and AST) as shown in (Table 3). When rats were pretreated with BPM (250mg/kg and 500mg/kg) and ranitidine, there were significant reductions in serum concentration of these markers, P<0.01, P<0.05.

184

185

Table 3. Effect of BPM extract on liver functions tests in ethanol induced gastric ulcers

Group	Dose(mg/kg)	ALT(IU/L)	AST(IU/L)
Ethanol	--	65.98±2.5	353±2.1
BPM	250	56.08±2.1*	325±7.1**
BPM	500	45.44±2.0**	305±4.8**
Ranitidine	50	55.18±3.5*	331±3.07*

186

187

188

189

Results as mean±S.E.M. for six rats. Statistical comparison was performed using ANOVA followed by the Dunnett's test. **P<0.01, *P<0.05 when compared with control group.

3.3.3. Indomethacin induced mucosal lesions

190

191

192

193

Indomethacin (20mg/kg, p.o.) administration induced severe gastric mucosal damage. BMP, at tested doses 250 and 500mg/kg, showed significant gastroprotective effect against gastric lesions, P<0.01. Standard drug ranitidine (50mg/kg, p.o.) included in the study as positive control also exhibited significant protection, P<0.01 (Table1 and Figure 2& 3).

194

195


Figure 2. Macroscopic view of rat stomach in indomethacin induced gastric ulcer



196


197

Indomethacin Group



Ranitidine Group

198



BPM (250mg/kg)



BPM (500mg/kg)



199

200

201

202

Figure 3. Histopathology of rat stomach in indomethacin induced gastric ulcer




203

204

Indomethacin group

Ranitidine Group



205

206

BPM (250mg/kg)

BPM (500mg/kg)

207 Results showed that rats pretreated with BPM at doses of 250 and 500mg/kg and ranitidine
208 improved the histopathology of rat stomach compared to indomethacin (control) group. Ulcer
209 induced group showed severe disruption to the epithelium and deep mucosa.

210

4. DISCUSSION

211

212 Various noxious stimuli of endogenous (acid and pepsin) and exogenous (drugs and alcohol)
213 origin, constantly comes in contact with gastric mucosa. Gastric mucosal defensive
214 mechanism, like mucosal blood flow, bicarbonate and mucus secretion protect the gastric
215 mucosa from damage. It is generally believed that it results from an imbalance between
216 aggressive factor (acid, pepsin) and defensive factors (mucous secretions, prostaglandins)
217 [32]. Therapeutic agents including different plant extracts are used to regain the balance by
218 inhibiting the gastric acid secretion or by increasing the mucous production, stabilizing the
219 surface epithelial cells. Herbs are one of the most promising sources of new drugs as these
220 are free of or having very less side effects and adverse reactions.

221

222 The methanol extract of *B. prionitis* was used to evaluate gastro protective activity by using
223 ethanol and indomethacin induced gastric ulcers. Ethanol is one of the most widely used
224 agents in experimental models to evaluate the gastroprotective activity in rats [33,34]. The
225 acute effect of ethanol induced ulcer has been proved to be its rapid penetration into gastric
226 mucosa, which may cause more mucosal permeability and release of vasoactive mediators
227 such as leukotrienes C4 (LTC 4), endothelin-1(ET-1) and histamine. The vasoactive
228 mediators induce blood flow stasis in mucus membrane circulation; which increase the
229 lesions in mucosa [35,36]. In addition, ethanol also induces reduction in mucus production,
230 gastric mucosal blood flow, endogenous glutathione, bicarbonate secretion, prostaglandin
231 (PG) production, tissue level of DNA, RNA and proteins, which leads to tissue injury [37-39].
232 The other factor responsible may be formation of reactive oxygen species, which cause an
233 imbalance between oxidant and antioxidant process, that results rupture of blood vessels,
234 thus contributes to the haemorrhage, tissue necrosis and disrupting the protective mucosal
235 barrier [40,41]. Indomethacin is an indole derivative act not only as anti-inflammatory but
236 also analgesic and antipyretic. This drug has better ulcerogenic potential than other NSAIDS
237 [42] Indomethacin reduces the PG by inhibiting both COX enzymes, that impares the
238 mucosal barrier thus rendering gastric mucosa more susceptible to injury [43,44]. Further,
COX-1 inhibition leads to the release of ET-1 which has been shown to induce mucosal

239 injury and inhibition of PGs activate the neutrophils and the local release of reactive oxygen
240 specie (ROS) and thus starts gastric injury [45]. In the present study, *B. prionitis* leaves were
241 found to possess remarkable gastroprotective activity compared to the control. It is plausible
242 to suggest that antiulcer activity is associated with *B. prionitis* ability to antagonize these
243 aggressive factors while augmenting the defensive mucosal factors that protect the gastric
244 mucosa from injury. To study the side effects of *B. prionitis* on liver, serum AST and ALT
245 were determined in ethanol induced gastric ulcer model. Control group animals showed,
246 increase of serum concentration of these enzymes that indicates hepatic injury since level of
247 these enzymes increases in chemically triggered tissue injury [46]. *B. prionitis* administration
248 decreased the levels of AST and ALT that shows its tissue damage preventing action.

249 The preliminary phytochemical analysis indicated the presence of flavonoids, sterols,
250 glycosides, saponins. These secondary metabolite classes are related to gastro protective
251 activity. There are many studies related to the antiulcerogenic properties of flavonoids [47,
252 48]. Leaves of the plant also contain saponins. Saponins exhibit ulcer protective effect by
253 selective inhibition of prostaglandin F_{2α} and by protection of gastric mucosa [40,49]. In view
254 of this fact it is suggested that gastro protection elucidated by the methanol extract of *B.*
255 *prionitis* may be related to the presence of these phytoconstituents.

256 5. CONCLUSION

257

258 The results provide support for the traditional use of this plant in the treatment of gastric
259 ulcer. However, the data so far obtained do not indicate the specific mechanism(s)
260 responsible for the antiulcer activity. Further studies are required to isolate the active
261 components and to elucidate their mechanism of action. In conclusion, the results show that
262 methanolic extract of *Barleria prionitis* Linn. possess gastro protective activity.

263 ACKNOWLEDGMENTS

264 The authors thank Director, Institute of Pharmaceutical Sciences, Kurukshetra University,
265 Kurukshetra, Haryana, India for providing excellent research facilities. The authors are
266 thankful to University Grant Commission, New Delhi, India for providing financial support as
267 Minor Research Project.

268 COMPETING INTERESTS

269 The authors declare that they have no competing interests.

270 AUTHOR'S CONTRIBUTION

271 1st author wrote the protocol, performed the study and statistical analysis 2nd author
272 designed the study, managed the analysis, write the first draft of manuscript, 3rd author
273 helped in the literature study and finally all the authors read and approved the final
274 manuscript.

275 ETHICAL APPROVAL

276 All authors hereby declare that, Principles of laboratory animal care (NIH publication No.85-
277 23, revised 1985) were followed. All the experimental procedures and protocols used in the
278 study were reviewed by the Institutional Animal Ethics Committee (IAEC) (Register Number:
279 562/GO/02/a/CPCSEA) and were in accordance with the CPCSEA guidelines, Government
280 of India.

281

- 283 1. Jainu M, Devi CSS. Antiulcerogenic and ulcer healing effects of *Solanum nigrum* (L.)
284 on experimental ulcer models: Possible mechanism for the inhibition of acid
285 formation. J Ethnopharmacol. 2006;104:156-163.
- 286 2. Klein-Júnior LC, Gandolfi RB, Santin JR, Lemos M, Cechinel FV, Andrade SF.
287 Antiulcerogenic activity of extract, fractions, and some compounds obtained from
288 *Polygala cyparissias* St Hillaire & Moquin (Poligalaceae). Naunym-Schmiedberg's
289 Archives of Pharmacology. 2010;381:121-126.
- 290 3. Anonumous. How to treat acidity in stomach and what are its symptoms? Simple
291 Remedies. 2011. Accessed on 23 April 2013. Available : www.simple-remedies.com/
- 292 4. Khan R. Gastritis-Acute & Chronic Gastritis. Hpathy. 2007. Accessed on 23 April
293 2013. Available : health.hpathy.com/gastritis-symptoms-treatment-cure.asp.
- 294 5. Muralidharan P, Srikanth J. Antiulcer activity of *Morinda citrifolia* Linn. fruit extract. J
295 Sci Res. 2009;1(2):345-352.
- 296 6. Lima ZP, Severi JA, Pellizzon CH, Brito ARMS, Solis PN, Caceres A et al. Can the
297 aqueous decoction of mango flowers be used as antiulcer agent? J
298 Ethnopharmacol. 2006;106:29-37.
- 299 7. Grossman MI, Elashoff JD. Peptic ulcer: A guide for the practicing physician. Year
300 Book Medical Publishers; 2009.
- 301 8. Chan FK, Leung WK. Peptic ulcer disease. Lancet. 2002;360:933-941.
- 302 9. Malfertheiner P, Chan FKL, McColl KEL. Lancet. 2009;374:1449-1461.
- 303 10. Sheen E, Triadafilopoulos G. Adverse effects of long- term proton pump inhibitor
304 therapy. Digestive Diseases and Sciences. 2011;56:931-950.
- 305 11. Bighetti AE, Antonio MA, Kohn LK, Rehder VLG, Foglio MA, Possenti A, et al.
306 Antiulcerogenic activity of a crude hydroalcoholic extract and coumarin isolated from
307 *Mikania laevigata* Schultz Bip. Phytomedicine. 2005;12:72-77.
- 308 12. Rodriguez A, Theoduloz C, Yanez T, Becerra J, Schmeda-Hirschmann G.
309 Gastroprotective and ulcer healing affect of ferruginol in mice and rats: assessment
310 of its mechanism of action *in vitro* models. Life Sci. 2006;79:2503-2509.
- 311 13. Amoo SO, Finnie JF, van Staden J. *In vitro* pharmacological evaluation of three
312 *Barleria* species. J Ethnopharmacol 2009;121:274-277.
- 313 14. Teotia P. Horticultural potential of *Barleria prionitis* L. in arid regions. J Econ Taxon
314 Bot 2000;24(2):251-253.
- 315 15. Chopra RN, Nayar SL, Chopra IC. In Glossary of Indian Medicinal Plants, CSIR:
316 New Delhi; 1965.
- 317 16. Gupta HM, Saxena VK. A new acylated luteolin-7-O- β -D-glucoside from the roots of
318 *Barleria prionitis* (Linn.). Nat Acad Sci Lett. 1984;7:187-189.
- 319 17. Khare CP. Indian Medicinal Plants: An Illustrated Dictionary. 1st ed. New York:
320 Springer Science; 2007.
- 321 18. Aneja KR, Joshi R, Sharma C. Potency of *Barleria prionitis* L. bark extracts against
322 oral disease causing strains of bacteria and fungi of clinical origin. New York Sci J.
323 2010;3:5-12.
- 324 19. Shukla P, Singh A, Gawri S, Alexende A, Sonwane S. *In vitro* propagation of
325 *Barleria prionitis* Linn and its antibacterial activity. Int J Pharma Prof Res. 2011;2:
326 198-200.

- 327 20. Nadkarni AK. *Barleria prionitis*. Linn. In Dr. K. M. Nadkarni's. Indian Materia Medica,
328 3rd edn. Popular Book Depot: Bombay; 1994.
- 329 21. Kirtikar KR, Basu BD. *Barleria prionitis* Linn. In Indian Medicinal Plants 3rd edn..
330 Blatter E, Caicus JF, Mhaskar KS(eds) Sri Satguru Publication: Delhi; 2000.
- 331 22. Singh B, Bani S, Gupta DK, Chandan BK, Kaul A. Anti-inflammatory activity of TAF
332 an active fraction from the plant *Barleria prionitis* Linn. J Ethnopharmacol
333 2003;85:187-193.
- 334 23. Khadse CD, Kadke RB. Antiinflammatory activity of aqueous extract fractions of
335 *Barleria prionitis* L. roots. Asian J Plant Sci Res. 2011;1:63-68.
- 336 24. Singh B, Chandan BK, Prabhakar A, Taneja SC, Singh J, Qazi GN. Chemistry and
337 hepatoprotective activity of an active fraction from *Barleria prionitis* Linn. in
338 experimental animals. Phytother Res 2005;19:391-404.
- 339 25. Maji AK, Bhadra S, Mahapatra S, Banerji P, Banerjee D. Mast cell stabilization and
340 membrane protection activity of *Barleria prionitis* L. Pharmacog J. 2011;3:67-71.
- 341 26. Ata A, Kalhari KS, Samarasekera R. Chemical constituents of *Barleria prionitis* and
342 their enzyme inhibitory and free radical scavenging activities. Phytochem Lett 2009;
343 2:37-40.
- 344 27. Khandelwal KR. Practical pharmacognosy techniques and experiments. 3rd ed.
345 Pune: Nirali Prakashan; 1996, p. 171-172.
- 346 28. Mizui T, Doteuchi M. Effect of polyamines on acidified ethanol-induced gastric lesion
347 in rats. Jpn J Pharmacol. 1983;33(5):939-945.
- 348 29. Ganguly AK. A method for quantitative assessment of experimentally produced
349 ulcers in the stomach of albino rats. Experientia. 1969;25(11):1224.
- 350 30. Djahanguiri B. The production of acute gastric ulceration by indomethacin in the rat.
351 Scand J Gastroenterol. 1969;4(3):265-267.
- 352 31. Dijoseph JF, Eash JR, Mir GN. Gastric antisecretory and antiulcer effects of
353 WHR1582A, a compound exerting alpha-2 adrenoceptor agonist activity. J
354 Pharmacol Exp Ther. 1987;24(1):97-102.
- 355 32. Piper DW, Stiel DD. Pathogenesis of chronic peptic ulcer, current thinking and
356 clinical implications. Med Prog. 1986;2:7-10.
- 357 33. Akhtar AH, Ahmad KU. Antiulcerogenic evaluation of the methanolic extracts of
358 some indigenous medicinal plants of Pakistan in aspirin-ulcerated rats. J
359 Ethnopharmacol. 1995;46:1-6.
- 360 34. Atta AH, Soad MN, Mounair SM. Antiulcerogenic effect of some plant extracts.
361 Natural Product Radiance. 2005;4:258-263.
- 362 35. Wallace JL. Mechanisms of protection and healing: current knowledge and future
363 research. Am J Med. 2001;110:19-23.
- 364 36. Al-wabel NA, Hassan A, Abbas H, Mucosa H. Antiulcerogenic effect of camel milk
365 against ethanol induced gastric ulcers in rats. Webmed Central Veterinary Medicine.
366 2012;3(3):WHCDD2804.
- 367 37. Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins
368 in rats Prevention of gastric necrosis produced by alcohol, HC1, NaOH, hypertonic
369 NaCl and thermal injury. Gastroenterology. 1979;77:433-443.
- 370 38. Glavin GB, Szabo S. Experimental gastric mucosal injury: laboratory models reveal
371 mechanism of pathogenesis and new therapeutic strategies. Fed Am Soc Exp Boil J.
372 1992;42:111-116.

- 373 39. Germano MP, Sango R, Guglielmo M, De Pasquale R, Crissafi G. Effects of *P*
374 *teleopsis subcrosa* extract on experimental gastric ulcers and *H.pylori* growth. J
375 Ethnopharmacol. 1998;59:167-172.
- 376 40. Lewis DA, Hanson PJ. Antiulcer drugs of plant origin. Prog Med Chem. 1991;28:
377 201-231.
- 378 41. Sikiric P, Seiwerth S, Grabarevic Z, Rucman R, Petek M, Jagic V et al. The influence
379 of a novel pentadecaseptide BPC 157, on NG-nitro-L-arginine methylester and L-
380 arginine effect on stomach mucosal integrity and blood pressure. Eur J Pharmacol.
381 1997;332:23-33.
- 382 42. Batista LM, de Almeida ABA, Lima GR de M, Fálcao H de S, Ferreira AL, Magri L de
383 P et al. Gastroprotective effect of the ethanolic extract and fractions obtained from
384 *Syngonanthus bisulcatus* Rul. Rec Nat Prod. 2013;7(1):35-44.
- 385 43. Scarpignato C, Hunt RH. Nonsteroidal anti-inflammatory drug-related injury to the
386 gastrointestinal tract: clinical picture, pathogenesis, and prevention. Gastroenterol
387 Clin North Am. 2010;39:433-464.
- 388 44. Vane JR, Botting RM. Mechanism of action of non-steroidal anti-inflammatory drugs.
389 Am J Med. 1998;104:2S-8S.
- 390 45. Whittle BJ. Gastrointestinal effects of non-steroidal anti-inflammatory drugs. Fundam
391 Clin Pharmacol. 2002;17:301-313.
- 392 46. Myagmar BE, Shinno E, Ichiba T, Aniya Y. Antioxidant activity of medicinal herb
393 *Rhodococcum vitis-idaea* on galactosamine-induced liver injury in rats.
394 Phytomedicine. 2004;11:416-423.
- 395 47. Gracioso JS, Vilegas W, Hiruma-Lima CA, Souza Brito AR. Effects of tea from
396 *Turnera ulmifolia* L. on mouse gastric mucosa support the Turneraceae as a new
397 source of antiulcerogenic drugs. Biol Pharm Bull. 2002;25:487-491.
- 398 48. Gonzalez FG, Di Stasi LC. Anti-ulcerogenic and analgesic activities of the leaves of
399 *Wilbrandia ebracteata* in mice. Phytomedicine. 2002;9(2):125-134.
- 400 49. Aguwa CN, Okunji CO. Gastrointestinal studies of *Pyrenacantha staudtii* leaf
401 extracts. J Ethnopharmacol. 1986;15(1):45-55.